ModifiedPremera BluecrossPolicy N/A

Upper gastrointestinal (UGI) endoscopy (EGD) In Adults — coverage criteria

Medical necessity and site-of-service criteria for elective diagnostic and therapeutic upper gastrointestinal endoscopy (EGD) for individuals aged 19 and older; guidance for providers on when EGD is covered by Premera Blue Cross.

Policy Summary

PayerPremera Bluecross

PolicyUpper gastrointestinal (UGI) endoscopy (EGD) In Adults — coverage criteria

Policy CodePolicy N/A

Change TypeClarifications and multiple additions to indications

Effective DateJul 1, 202619d

Next Review DateN/A

Key ActionDocument an 8-week continuous daily PPI trial (or recurrence after stopping PPI) before referencing EGD for GERD/dyspepsia.

SourceLink

POLICY UPDATE CHANGES

Clarified that UGI is medically necessary for GERD or dyspepsia symptoms that persist despite 8 weeks of continuous daily PPI therapy or return after PPI discontinuation.

Added medically necessary statement for follow-up of known eosinophilic esophagitis and a two-month course of therapy under follow-up criteria.

Preoperative UGI prior to bariatric surgery changed from not medically necessary to medically necessary.

Added UGI is medically necessary to assess diarrhea when suspicious for small bowel disease (e.g., celiac disease) or IBD, and for treatment of bleeding lesions such as ulcers.

Added that UGI is medically necessary when performed for endoscopic ultrasound guided fine needle aspiration/biopsy(s) of adjacent organs or structures.

Changed policy title from 'for Adults' to 'In Adults' and added Site of Service Ambulatory Service Center (ASC) Select Diagnostic or Surgical Procedures criteria; added header that site of service review does not apply to IHS facilities.

Added that UGI is considered not medically necessary for confirming Helicobacter pylori eradication.

19+policy applies to individuals aged

8 wksPPI trial required before EGD

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

≥3 mominimum symptom duration before EGD

BMI ≥50morbid obesity threshold

2013–2024history entries

2026-07-01effective date

Medical Necessity and Indications for UGI Endoscopy (EGD)

Indications for EGD (per ACP, ACG, ASGE)

Covered when ANY of the following indications are met (medical necessity). Criteria reflect professional guidance from ACP, ACG, and ASGE and internal policy updates.

ANY of the following

Suspected or known upper gastrointestinal (UGI) malignancy or premalignant conditions (e.g., Barrett esophagus, dysplasia, esophageal or gastric cancer, familial adenomatous polyposis, Lynch syndrome/HNPCC, gastric intestinal metaplasia when clinically indicated).
Includes one evaluation for individuals with positive CDH1 mutation and Tylosis.
Alarm symptoms potentially attributable to an UGI source: iron deficiency anemia; GI bleeding/hematochezia or melena; unexplained weight loss (≥3 kg) since symptoms started; persistent or recurrent vomiting; palpable epigastric mass; dysphagia or odynophagia.
Endoscopy indicated to evaluate alarm features per ACP/ASGE guidance.
Evaluation or surveillance related to known UGI conditions where endoscopy will alter management: Barrett esophagus surveillance per pathology (high-grade dysplasia: repeat every 3 months after initial biopsy for 1 year, then annually; low-grade dysplasia: repeat at 6 months, then at 12 months and annually thereafter; no dysplasia: one repeat within 12 months then every 3 years if unchanged).
Surveillance intervals reflect policy and guideline harmonization.
Therapeutic or procedural indications: management of active or recent GI bleeding (including endoscopic hemostasis), banding/sclerotherapy for esophageal varices with planned surveillance until eradication and then periodic surveillance (1–3 months post-eradication, then every 6–12 months); dilation of strictures; removal of foreign bodies; endoscopic therapy of lesions (e.g., polypectomy, EMR); placement of feeding/drainage tubes; EUS-guided FNA/biopsy when sampling of adjacent organs/structures is required.
Includes treatment and follow-up of bleeding ulcers and variceal therapy per policy.
Initial evaluation in conditions that may modify management: preoperative assessment prior to bariatric surgery (when covered by contract or when another criterion met), evaluation prior to organ transplantation when UGI pathology may affect management, assessment after caustic ingestion, and assessment for suspected portal hypertension to document or treat esophageal varices.
Preoperative bariatric UGI is medically necessary when contract permits or other criteria are met.
Persistent upper abdominal symptoms (including GERD or dyspepsia) that have not responded to an adequate trial of medical therapy: typical GERD symptoms persistent despite appropriate PPI therapy (per ACG: 4–8 weeks or policy-specified 8 weeks continuous daily PPI), or recurrence of symptoms after discontinuing PPI; severe erosive esophagitis after a 2-month PPI course to assess healing and exclude Barrett esophagus; chest pain without cardiac cause when GERD evaluation indicated.
Guidance supports endoscopy after failed empiric therapy or when alarm symptoms or multiple risk factors for Barrett are present.
Screening or surveillance in higher-risk individuals: men ≥50 years with ≥5 years of GERD symptoms plus additional risk factors (nocturnal reflux, hiatal hernia, elevated BMI, tobacco use, central adiposity) for detection of Barrett esophagus or esophageal adenocarcinoma; surveillance for premalignant conditions as per individual pathology and guideline recommendations.
Apply surveillance intervals described above for Barrett esophagus.
Follow-up of known non-malignant conditions when indicated: follow-up of eosinophilic esophagitis, follow-up endoscopy for gastric/peptic/esophageal ulcers every ~2 months until healed, evaluation of suspected small-bowel disease (e.g., celiac, IBD) when upper endoscopy is required for diagnosis, and evaluation of persistent non-cardiac chest pain when other evaluations are unrevealing.
Includes policy statements on follow-up timing for ulcers and eosinophilic esophagitis.
Evaluation for suspected anatomic lesions or to obtain tissue diagnosis: confirmation and biopsy of radiologically demonstrated lesions (suspected neoplasm, gastric or esophageal ulcer), evaluation of upper tract stricture/obstruction, sampling of tissue or fluid, and confirmation of lesions seen on imaging when results will change management.
Consistent with ASGE recommendations.

Procedure Codes, Surveillance Intervals, and Key Timeframes

Covered CPT CodesCPTCovered

43235	Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure).
43238	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures).
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple.
43242	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis).

Policy coding historyCPT

43233-43270 (range referenced historically)

Multiple CPT codes for upper GI endoscopy were added or removed across revisions (specific codes 43233, 43253, 43254, 43266, 43270 added in 2014; many CPT codes removed as informational in 2015).

Removed CPT codesCPT

43236

CPT code removed from policy in 2014.

Barrett esophagus surveillance intervals

High-grade dysplasia surveillanceRepeat UGI every 3 months after the initial biopsy for 1 year, then annually thereafter.

Low-grade dysplasia surveillanceRepeat UGI at 6 months, then surveillance at 12 months and annually thereafter.

No dysplasia (metaplasia) surveillanceRepeat UGI one time within 12 months after initial biopsy; then every 3 years if pathology unchanged.

PPI trial duration

Required duration8 weeks of continuous daily proton pump inhibitor (PPI) therapy.

Context for use

Prior Authorization, Documentation, and Site-of-Service Guidance

Prior Authorization

Prior Authorization Required — Site of Service Review

Elective diagnostic or surgical upper GI (UGI) endoscopy may be reviewed for medical necessity and site‑of‑service. Prior authorization or a site‑of‑service review may be required to ensure the procedure is performed in the most appropriate, safe, and cost‑effective setting (ASC preferred when criteria met).

Site‑of‑service considerations include ASC availability within 30 miles, necessary equipment, physician privileges, patient age (≤18 exception), concurrent services requiring hospital outpatient setting, or clinical conditions increasing risk for complications (e.g., ASA III+, significant cardiac, pulmonary, liver, renal risks, morbid obesity, bleeding disorders).

Note

Medical Necessity Determination

Coverage determinations rely on documented clinical indications and a reasonable/necessary standard. UGI endoscopy is covered when medical necessity for the individual patient is demonstrated; conversely, it may be denied when policy criteria are not met (e.g., uncomplicated heartburn without prior conservative management).

Clinical Background and Purpose of UGI Endoscopy

Upper gastrointestinal endoscopy (EGD/UGI) uses a flexible endoscope inserted through the mouth to visualize the esophagus, stomach, and proximal duodenum. It is a diagnostic and therapeutic procedure that can identify causes of heartburn, dysphagia, bleeding, and allow interventions such as biopsy, polypectomy, foreign body removal, dilation, variceal therapy, and endoscopic treatment of bleeding lesions. Professional guidance emphasizes initial conservative management for non-alarm symptoms and reserving endoscopy for patients with alarm features, persistent symptoms despite therapy, or conditions where endoscopic findings will change management.

Key Definitions

Barrett esophagus — definition and cancer risk

DefinitionReplacement of normal squamous epithelium of the esophagus by metaplastic columnar or glandular epithelium due to GERD.

Cancer riskThis metaplasia predisposes the individual to esophageal adenocarcinoma; estimated progression risk is referenced in guideline literature and surveillance is recommended based on dysplasia grade.

Surveillance implicationDiagnosis of Barrett esophagus prompts endoscopic surveillance intervals stratified by dysplasia (no dysplasia, low-grade, high-grade).

Achalasia — definition

DefinitionAn esophageal motility disorder involving the smooth muscle of the esophagus and the lower esophageal sphincter (LES).

Clinical relevanceAchalasia is an indication for UGI endoscopy per policy to evaluate esophageal pathology and guide management.

Policy Updates and Change Log

2026-07-01effective_dateLatest

Policy effective date updated to July 1, 2026 (finalized following prior operational delays).

2026-06-01minor_update

Added header clarifying that site-of-service review does not apply to Indian Health Services (IHS) facilities.

2026-03-27administrative_effective_date_change

Policy Summary

PayerPremera Bluecross

PolicyUpper gastrointestinal (UGI) endoscopy (EGD) In Adults — coverage criteria

Policy CodePolicy N/A

Change TypeClarifications and multiple additions to indications

Effective DateJul 1, 202619d

Next Review DateN/A

Key ActionDocument an 8-week continuous daily PPI trial (or recurrence after stopping PPI) before referencing EGD for GERD/dyspepsia.

SourceLink

On This Page

PPI trial required before EGD for GERD/dyspepsia unless symptoms recur after PPI discontinuation or contraindication to PPI.

Alternative dosing noteGuidance references empiric PPI trials of 8 weeks once daily, or 4–8 weeks twice daily for refractory symptoms in some guideline contexts.

Follow-up interval for known erosive esophagitis

Follow-up course durationTwo months course of therapy for known erosive esophagitis prior to reassessment.

Follow-up actionRepeat UGI after approximately two months of PPI therapy to assess healing and rule out Barrett esophagus for severe erosive esophagitis.

Repeat testing guidanceRepeat endoscopy only if Barrett esophagus is found; otherwise further surveillance per pathology findings.

Documentation Required

Documentation Required — Alarm Features and High‑Risk Conditions

Document in the clinical notes the presence or absence of malignant indications and any alarm symptoms. Required alarm features to support medical necessity include anemia (iron deficiency), gastrointestinal bleeding, dysphagia, persistent or recurrent vomiting, unintentional weight loss (≥3 kg), or an epigastric mass. Also document high‑risk non‑malignant conditions needing follow‑up or treatment (e.g., prior adenomatous or sessile polyps, CDH1 mutation, portal hypertension/cirrhosis, eosinophilic esophagitis, erosive esophagitis, history of gastric surgery, esophageal varices).

Alarm features: anemia, bleeding, dysphagia, recurrent vomiting, weight loss ≥3 kg, epigastric mass.
High‑risk non‑malignant conditions: prior adenomatous/sessile polyps (gastric/duodenal/esophageal), CDH1 mutation, portal hypertension/cirrhosis, eosinophilic or erosive esophagitis, history of gastric surgery, esophageal varices.

Step Therapy

Conservative Management — Empiric PPI Trial Required

For GERD or dyspepsia without alarm features, attempt an empiric proton pump inhibitor (PPI) trial prior to endoscopy: an 8‑week trial of once‑daily PPI before a meal is recommended. For refractory symptoms, a trial of twice‑daily PPI for 4–8 weeks may be appropriate. Document medication name, dose, duration, response, and whether symptoms recurred after stopping therapy. H2RA therapy may be used only if PPIs are contraindicated or not tolerated.

Empiric PPI: 8 weeks once daily before a meal is recommended for classic GERD without alarm features.
Refractory symptoms: 4–8 weeks twice daily PPI may be considered.
Document continuous daily PPI therapy for 8 weeks or note symptom recurrence after discontinuation if seeking endoscopy without the full trial.

Denial Risk

Conservative Management Preference, H. pylori, and Benefit Verification

In the absence of a clear cancer diagnosis, conservative medical management should precede invasive diagnostics such as UGI endoscopy. UGI is not medically necessary for confirming H. pylori eradication. Verify member benefits — contracts differ and this medical policy is a guide; consult the member benefit booklet or customer service for coverage specifics.

Do not perform routine endoscopy when symptoms are chronic, non‑progressive, and likely functional without first attempting conservative therapy.
UGI endoscopy is generally not indicated solely to confirm Helicobacter pylori eradication.
Member benefit verification is required; this policy does not apply to Medicare Advantage.

Associated symptomsPresents with dysphagia and may require endoscopic evaluation or therapeutic intervention.

EGD / Esophagogastroduodenoscopy — definition

DefinitionDiagnostic endoscopic examination of the esophagus, stomach, and duodenum using a flexible endoscope inserted via the mouth (also called EGD or UGI endoscopy).

PurposeUsed to visualize upper GI mucosa for diagnosis (eg, GERD, dysphagia, bleeding) and to perform certain therapies under light IV sedation.

SynonymEsophagogastroduodenoscopy (EGD) is synonymous with upper gastrointestinal (UGI) endoscopy and gastroscopy.

Upper gastrointestinal (UGI) endoscopy / EGD — procedure definition

Procedure definitionUpper gastrointestinal (UGI) endoscopy is a procedure using a flexible endoscope inserted via the mouth to visualize the esophagus, stomach, and upper duodenum; primarily diagnostic and may include therapeutic interventions.

Typical settingUsually performed under light sedation with intravenous medication.

Common indicationsUsed to evaluate severe heartburn (dyspepsia), dysphagia, persistent vomiting, and frank GI bleeding.

Non-cardiac chest pain (NCCP) — definition and relevance

DefinitionNon-cardiac chest pain (NCCP) describes chest pain similar to angina in individuals whose cardiac evaluation excluded heart disease.

Relevance to GI evaluationAfter cardiac causes are excluded, persistent chest pain may warrant gastrointestinal evaluation including objective testing for GERD and/or endoscopy.

Clinical recommendationACG advises excluding cardiac causes before initiating GI evaluation for NCCP.

UGI — shorthand definition for adult EGD procedures

Shorthand definitionUGI refers to upper gastrointestinal endoscopy (EGD) procedures performed in adults.

ScopeIncludes diagnostic inspection of the esophagus, stomach, and duodenum and may include therapeutic interventions when indicated.

Terminology noteUGI and EGD are used interchangeably in this policy for adult endoscopic procedures.

Endoscopic ultrasound guided fine needle aspiration/biopsy (EUS-FNA/FNB) — definition and indication for combined use with UGI

DefinitionEndoscopic ultrasound guided fine needle aspiration/biopsy (EUS‑FNA/FNB) uses endoscopic ultrasound to guide needle sampling of adjacent organs or structures (eg, pancreas, liver) during UGI procedures.

Indication for combined use with UGIUGI is considered medically necessary when performed to facilitate EUS‑guided FNA/FNB of adjacent organs or structures.

Therapeutic/diagnostic roleAllows tissue diagnosis of lesions adjacent to the GI tract during the same endoscopic session.

Policy effective date moved from May 1, 2026 to July 1, 2026 due to operational readiness; administrative timing change.

2026-02-24administrative_effective_date_change

Policy effective date moved from March 4, 2026 to May 1, 2026 due to operational readiness; administrative timing change.

2026-02-01criteria_update

Modified UGI indication to specify 'Individuals with newly diagnosed (within one year) pernicious anemia.'

2025-12-01coverage_revision

Changed policy title wording and added Site of Service Ambulatory Surgical Center (ASC) Select Diagnostic or Surgical Procedures criteria (effective March 4, 2026 following 90-day provider notification).

2025-09-01not_medically_necessary_added

Added statement that UGI is considered not medically necessary for confirming Helicobacter pylori eradication.

2024-05-01clarification

Clarified UGI is medically necessary for family history of upper GI cancer in a first-degree relative and refined related policy language.

2024-03-01surveillance_update

Updated Barrett esophagus low-grade dysplasia surveillance: repeat UGI at 6 months, then at 12 months and annually thereafter.

2023-10-01added_indication

Added that UGI is medically necessary when performed for endoscopic ultrasound guided fine needle aspiration/biopsy(s) of adjacent organs or structures.

2023-02-01not_medically_necessary_added

Added that UGI performed for surveillance of individuals with gastric intestinal metaplasia is considered not medically necessary.

2023-01-01coverage_change

Preoperative UGI prior to bariatric surgery was changed from not medically necessary to medically necessary; added several therapeutic and follow-up indications including treatment of bleeding lesions and follow-up UGI for ulcers every 2 months until healed.

2022-09-02criteria_clarification

Modified UGI medically necessary statement for GERD/dyspepsia to require persistence despite 8 weeks of continuous daily PPI therapy or evaluation for symptoms returning after PPI discontinuation (change effective 09/02/22).

2022-06-01criteria_addition

Added follow-up of known eosinophilic esophagitis and clarified two-month course of therapy under follow-up criteria for erosive esophagitis.

2021-11-01annual_review

Annual review completed; references updated and policy statement unchanged.

2013-06-10policy_inception

New policy created (initial policy entry) with provider notification procedures and 90-day hold for implementation.